China 
Africa 
Explore chapters and articles related to this topic
Unprecedented Innovations in Electrochemical Biosensing Approaches for Medical Applications
Published in Sibel A. Ozkan, Bengi Uslu, Mustafa Kemal Sezgintürk, Biosensors, 2023
Susana Campuzano, María Pedrero, Maria Gamella, Rebeca M. Torrente-Rodríguez, José M. Pingarrón
An electrochemical leucine-benzyl ferrocene carbamate (Leu-FC) based sensing platform has been reported for (i) in situ monitoring of Leucine aminopeptidase (LAP) activity, a potential biomarker for liver malignancy, in live cells, (ii) following the effects of chemotherapy toward liver carcinoma via monitoring LAP activity changes during clinical treatment, and (iii) studying drug resistance in HepG2 cancer cells against cisplatin from the real time assay of cellular LAP activity. All assays were done in vitro (149). Lee et al. (150) reported an electrochemical deposition and co-reduction methodology to prepare Pt nanoparticles (PtNP)-decorated, porous reduced graphene oxide (rGO)–CNT nanocomposites on a PtNP-deposited screen-printed carbon electrode for in vitro detection of H2O2 released from prostate cancer cells after phorbol 12-myristate 13-acetate (PMA) stimulation. Peritoneal carcinomatosis, induced by the intraperitoneal dissemination of several digestive and gynecological malignancies, constitutes a severe stage of cancers that need to be frequently monitored. Xu et al. (151) have recently reported the possibility to monitor it through in vivo and real-time peritoneal glucose detection using a Pt nanotree microelectrode with wireless, battery-free and flexible electrochemical patch. The system was tested in vivo by implanting the microelectrode in a minimally invasive way in the rat peritoneal cavity.
Asbestos exposure and mesothelioma
Published in Dorsett D. Smith, The Health Effects of Asbestos, 2015
Advances have been made in the treatment of peritoneal mesotheliomas, namely intraperitoneal chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. Intraperitoneal chemotherapy, involving the administration of certain chemotherapeutic agents directly to the intraperitoneal cavity, was developed as a novel therapeutic strategy early in the 1950s. Intraperitoneal administration of chemotherapy results in higher intraperitoneal concentrations of the cytotoxic medications, particularly when heated, resulting in minimal systemic exposure compared with intravenous administration, which in turn may increase the efficacy of these agents with a substantial reduction in systemic toxicity. Intraperitoneal chemotherapy was used successfully in peritoneal surface malignancies, including malignant peritoneal mesothelioma, pseudomyxoma peritonei, malignant ascites, sarcomatosis, and peritoneal carcinomatosis from gastrointestinal and ovarian cancers. The advent of cytoreduction with hyperthermic intraperitoneal chemotherapy has dramatically improved survival outcomes, with wide median survival estimates of between 2.5 and 9 years. (Elias D, Goéré D, Dumont F et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014;50(2):332–40; Raza A, Huang WC, Takabe K. Advances in the management of peritoneal mesothelioma. World J Gastroenterol 2014;20(33):11700–12.)
Colonic stents for malignant bowel obstruction: current status and future prospects
Published in Expert Review of Medical Devices, 2019
Vittorio Maria Ormando, Rossella Palma, Alessandro Fugazza, Alessandro Repici
Unfortunately, also SEMS in this setting is associated with a quite high risk of failure and/or complications. Clinical success rates in ECM patients vary considerably in the existing literature, probably because authors have used different definitions of clinical success or because of limited numbers of cases in published series. In the largest series published up to now, including 187 patients, technical success rate was 75.9% and clinical success rate 54.5% confirming that colonic stent placement for MBO due to extrinsic compression is less effective than for palliation of primary cancer [20]. According to the result of this large series, patients with peritoneal carcinomatosis and multifocal disease have lower technical and clinical success and increased risk of complications.
Clinical effectiveness and versatility of a sealing hemostatic patch (HEMOPATCH) in multiple surgical specialties
Published in Expert Review of Medical Devices, 2018
Kevin M. Lewis, Shelly Ikeme, Tolu Olubunmi, Carl Erik Kuntze
Torres et al. [47] presented research abstract data derived from an observational study and noted that intestinal suture or bowel anastomosis reinforcement with HEMOPATCH might contribute to the reduction of surgical complications such as dehiscence, leaks, and fistula formation. The study included 12 peritoneal carcinomatosis patients who underwent complete cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy (CRS-HIPEC using coliseum technique). In all subjects, HEMOPATCH was applied to cover up to 1 cm beyond the 5 colo-colonic, 3 ileorectal, and 4 jejunojejunal mechanical suture lines. Compared to an anastomotic dehiscence rate of 7.5% in series of 305 CRS-HIPEC patients, clinical and radiological examinations revealed no anastomotic leakage or dehiscence in any of the 12 patients treated with HEMOPATCH.